Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KYNU | Q16719 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616770 | 0.88 | CTSL (0.57) | CTRB1CTSLCTSBNPC1RAB9A | |
| SCHEMBL5544627 | 0.84 | NPC1 (0.53) | CTRB1ALDH1A1ATMNPC1RAB9A | |
| SCHEMBL8198038 | 0.82 | CTRB1 (0.58) | CTRB1TRPM8ALDH1A1ALOX15CTSK | |
| SCHEMBL8198203 | 0.82 | CTRB1 (0.58) | CTRB1TRPM8ALDH1A1ALOX15CTSK | |
| SCHEMBL28141917 | 0.82 | CTRB1 (0.58) | CTRB1TRPM8ALDH1A1ALOX15CTSK | |
| SCHEMBL9074306 | 0.82 | CTRB1 (0.58) | CTRB1TRPM8ALDH1A1ALOX15CTSK | |
| SCHEMBL3331611 | 0.82 | TRPM8 (0.67) | CTRB1TRPM8ALDH1A1ALOX15CTSK | |
| SCHEMBL7151822 | 0.82 | ALDH1A1 (0.74) | TRPM8ALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL329686 | 0.82 | ALDH1A1 (0.74) | TRPM8ALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL13534727 | 0.81 | NPC1 (0.65) | CTRB1TRPM8ALDH1A1ALOX15CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CTRB1 2545/4885TRPM8 542/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.